

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/080646-2025>

Award

Xenium Single-cell Spatial Transcriptomics/Proteomics Instrument for Medicines Discovery Catapult

MEDICINES DISCOVERY CATAPULT LIMITED

UK5: Transparency notice - Procurement Act 2023 - [view information about notice types](#)

Notice identifier: 2025/S 000-080646

Procurement identifier (OCID): ocds-h6vhtk-05f0dd ([view related notices](#))

Published 8 December 2025, 2:22pm

Scope

Description

..

Contract 1

Supplier

- 10x Genomics Inc

Contract value

- £344,000 excluding VAT
- £412,800 including VAT

Above the relevant threshold

Earliest date the contract will be signed

17 December 2025

Contract dates (estimated)

- 17 December 2025 to 17 December 2026
- Possible extension to 18 December 2030
- 5 years, 2 days

Description of possible extension:

The contract may be extended for a further four twelve month periods to extend the original warranty.

Main procurement category

Goods

Options

The right to additional purchases while the contract is valid.

The contract may be extended to purchase four 12 month warranty extensions.

CPV classifications

- 38000000 - Laboratory, optical and precision equipments (excl. glasses)

Contract locations

- UK - United Kingdom

Other information

Conflicts assessment prepared/revised

Yes

Procedure

Procedure type

Direct award

Direct award justification

Single supplier - technical reasons

Medicines Discovery Catapult (MDC) intends to award a contract for the purchase of a Xenium single-cell spatial transcriptomics/proteomics instrument to 10X Genomics, on the basis that no reasonable alternative or substitute exists which meets the specific technical and operational requirements of the organisation.

Independent comparative studies have demonstrated that alternative platforms currently on the market exhibit significantly higher levels of background noise, reducing data quality in single cell spatial analysis. MDC has verified these performance results and determined that the Xenium system is uniquely capable of delivering the sensitivity and precision required for our research and service activities.

Beyond this the Xenium platform also offers operational advantages. It enables the use of panels with a low minimum run size, which aligns closely with the typical experimental scale within MDC. Competing systems require substantially higher minimum slide numbers, making them unsuitable and leading to inefficient use of resources.

In addition, acquiring the Xenium system will strengthen MDC's national role by providing UK drug discovery organisations access to a capability that is not currently available within any UK based CRO. This avoids duplication with existing commercial provider and ensures MDC can offer new and complementary capabilities to the wider life sciences community.

Supplier

10x Genomics Inc

- Public Procurement Organisation Number: PBMJ-4568-WMPX

6230 Stoneridge Mall Road

Pleasanton

CA 94588-3260

United States

Email: tenders@10xgenomics.com

Website: <https://www.10xgenomics.com/>

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Contract 1

Contracting authority

MEDICINES DISCOVERY CATAPULT LIMITED

- Companies House: 09928547
- Public Procurement Organisation Number: PJPQ-6911-DQYY

Block 35g, Mereside Alderley Park

Macclesfield

SK10 4ZF

United Kingdom

Email: procurement@md.catapult.org.uk

Region: UKD62 - Cheshire East

Organisation type: Public authority - sub-central government